Dupilumab Treatment is Not Associated with Increased Risk of Overall Skin Infections [Letter]
Simmi Wiggins,1,* Noah A Levit2,* 1Sanofi, 410 Thames Valley Park Dr, Reading, RG6 1PT, UK; 2Regeneron Pharmaceuticals Inc, Tarrytown, NY, 10591, USA*These authors contributed equally to this workCorrespondence: Simmi Wiggins, Sanofi, 410 Thames Valley Park Dr, Reading, RG6 1...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-05-01
|
| Series: | ImmunoTargets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/dupilumab-treatment-is-not-associated-with-increased-risk-of-overall-s-peer-reviewed-fulltext-article-ITT |